TY - JOUR T1 - ▼Romosozumab for osteoporosis JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 169 LP - 173 DO - 10.1136/dtb.2021.000027 VL - 59 IS - 11 A2 - , Y1 - 2021/11/01 UR - http://dtb.bmj.com/content/59/11/169.abstract N2 - Generic name: Romosozumab Brand name: Evenity Formulation: 105 mg solution for injection in a pre-filled pen Market Authorisation holder: UCB Pharma Limited Indication: treatment of severe osteoporosis in postmenopausal women at high risk of fracture Dose: 210 mg romosozumab (administered as two subcutaneous injections of 105 mg each) once a month for 12 months. It is recommended that patients begin antiresorptive therapy after completing treatment with romosozumab. Cost: £427.75 for two pre-filled pens each containing 105 mg romosozumab Classification: Prescription only medicine (POM) subject to additional monitoring (▼) ER -